WO2006065827A3 - Cell lines for production of replication-defective adenovirus - Google Patents

Cell lines for production of replication-defective adenovirus Download PDF

Info

Publication number
WO2006065827A3
WO2006065827A3 PCT/US2005/045097 US2005045097W WO2006065827A3 WO 2006065827 A3 WO2006065827 A3 WO 2006065827A3 US 2005045097 W US2005045097 W US 2005045097W WO 2006065827 A3 WO2006065827 A3 WO 2006065827A3
Authority
WO
WIPO (PCT)
Prior art keywords
cell lines
production
complement
replication
defective adenovirus
Prior art date
Application number
PCT/US2005/045097
Other languages
French (fr)
Other versions
WO2006065827A2 (en
WO2006065827A9 (en
Inventor
John A Howe
Scott J Sherrill
Ken Wills
Ii Robert Orville Ralston
Original Assignee
Canji Inc
John A Howe
Scott J Sherrill
Ken Wills
Ii Robert Orville Ralston
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Canji Inc, John A Howe, Scott J Sherrill, Ken Wills, Ii Robert Orville Ralston filed Critical Canji Inc
Priority to EP05853909A priority Critical patent/EP1831352B1/en
Priority to JP2007545722A priority patent/JP4621743B2/en
Priority to AT05853909T priority patent/ATE516343T1/en
Priority to MX2007007145A priority patent/MX2007007145A/en
Priority to CA2590943A priority patent/CA2590943C/en
Priority to CN2005800480722A priority patent/CN101208425B/en
Publication of WO2006065827A2 publication Critical patent/WO2006065827A2/en
Publication of WO2006065827A9 publication Critical patent/WO2006065827A9/en
Publication of WO2006065827A3 publication Critical patent/WO2006065827A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351—Methods of production or purification of viral material
    • C12N2710/10352—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10361—Methods of inactivation or attenuation
    • C12N2710/10362—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor

Abstract

The present invention provides cell lines for the production of E1-deleted adenovirus (rAd) vectors that complement E1A and E1B functions. The present invention also provides cell lines for the production of E1- and E2-deleted adenovirus vectors that complement E1A, E1B and E2B polymerase functions. The invention provides particular cell lines that complement E1A function by insertion of an E1A sequence containing mutations in the 243R and 289R proteins and an E1B sequence comprising the E1B-55K gene. Production yields in the resulting producer cell lines, designated SL0003 and SL0006, were similar to those obtained from 293 cells without generation of detectable recombinant replication competent adenovirus (“RCA”).
PCT/US2005/045097 2004-12-13 2005-12-12 Cell lines for production of replication-defective adenovirus WO2006065827A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
EP05853909A EP1831352B1 (en) 2004-12-13 2005-12-12 Cell lines for production of replication-defective adenovirus
JP2007545722A JP4621743B2 (en) 2004-12-13 2005-12-12 Cell lines for the production of replication-deficient adenoviruses.
AT05853909T ATE516343T1 (en) 2004-12-13 2005-12-12 CELL LINES FOR PRODUCING REPLICATION DEFECTIVE ADENOVIRUS
MX2007007145A MX2007007145A (en) 2004-12-13 2005-12-12 Cell lines for production of replication-defective adenovirus.
CA2590943A CA2590943C (en) 2004-12-13 2005-12-12 Cell lines for production of replication-defective adenovirus
CN2005800480722A CN101208425B (en) 2004-12-13 2005-12-12 Cell lines for production of replication-defective adenovirus

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US63556104P 2004-12-13 2004-12-13
US60/635,561 2004-12-13
US67448805P 2005-04-25 2005-04-25
US60/674,488 2005-04-25

Publications (3)

Publication Number Publication Date
WO2006065827A2 WO2006065827A2 (en) 2006-06-22
WO2006065827A9 WO2006065827A9 (en) 2006-08-24
WO2006065827A3 true WO2006065827A3 (en) 2006-10-12

Family

ID=36282846

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/045097 WO2006065827A2 (en) 2004-12-13 2005-12-12 Cell lines for production of replication-defective adenovirus

Country Status (8)

Country Link
US (1) US7851218B2 (en)
EP (1) EP1831352B1 (en)
JP (2) JP4621743B2 (en)
CN (1) CN101208425B (en)
AT (1) ATE516343T1 (en)
CA (1) CA2590943C (en)
MX (1) MX2007007145A (en)
WO (1) WO2006065827A2 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5213298B2 (en) 2002-05-27 2013-06-19 ホルム，ペル・ゾンネ New use of adenovirus and nucleic acid encoding it
JP2007511211A (en) 2003-11-14 2007-05-10 ホルム，ペル・ゾンネ New use of adenovirus and nucleic acid encoding it
CN101208425B (en) 2004-12-13 2011-01-26 坎吉有限公司 Cell lines for production of replication-defective adenovirus
JP5435871B2 (en) * 2004-12-31 2014-03-05 ホルム，ペル・ゾンネ E1-minus adenovirus and use thereof
CA2633087C (en) 2005-12-12 2014-12-02 Canji, Inc. Adenoviral expression vectors
WO2011046757A2 (en) * 2009-10-12 2011-04-21 Rajabrata Sarkar Accelerating thrombus resolution through augmentation of p53 activity
JP6757119B2 (en) 2011-10-05 2020-09-16 ジェンヴェック エルエルシー Afen adenovirus (gorilla) or adenovirus vector, and how to use
CA2850627A1 (en) 2011-10-05 2013-04-11 Genvec, Inc. Affenadenovirus (gorilla) or adenoviral vectors and methods of use
US9617560B2 (en) 2011-10-05 2017-04-11 Genvec, Inc. Simian (gorilla) adenovirus or adenoviral vectors and methods of use
WO2013077645A1 (en) * 2011-11-24 2013-05-30 주식회사 바이로메드 Adenovirus producing novel cell line and the use thereof
WO2013180967A1 (en) 2012-05-29 2013-12-05 Genvec, Inc. Herpes simplex virus vaccine
CN106913865A (en) 2013-04-18 2017-07-04 阿尔莫生物科技股份有限公司 The method that disease and illness are treated using interleukin 10
MX2018002298A (en) 2015-08-25 2018-07-06 Armo Biosciences Inc Methods of using interleukin-10 for treating diseases and disorders.
CN110832072B (en) * 2017-04-21 2023-11-07 真基因太科公司 Cell line for producing non-replicating adenovirus and method for preparing said cell line
EP4286055A3 (en) * 2017-07-10 2024-02-28 Gen-Probe Incorporated Analytical systems and methods for nucleic acid amplification using sample assigning parameters
MX2021005980A (en) 2018-11-21 2021-08-11 Mayo Found Medical Education & Res Adenoviruses and methods for using adenoviruses.
AU2021251718A1 (en) * 2020-04-07 2022-11-10 Lung Biotechnology Pbc Adenoviral expression vector and methods and cell lines for production
CN113736780A (en) * 2020-05-28 2021-12-03 暨南大学 BCBL1 cell line with p300 gene knockout function as well as construction method and application thereof
CN112156181A (en) * 2020-09-29 2021-01-01 广州恩宝生物医药科技有限公司 Adenovirus quadrivalent vaccine
CN117264902A (en) * 2022-06-15 2023-12-22 上海元宋生物技术有限公司 Construction method and application of adenovirus packaging and production cell line

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6835557B1 (en) 1980-01-08 2004-12-28 Biogen, Inc. DNA sequences, recombinant DNA molecules and processes for producing human interferon-like polypeptides
TW442569B (en) 1993-10-25 2001-06-23 Canji Inc Recombinant adenoviral vector
US6210939B1 (en) 1993-10-25 2001-04-03 Canji, Inc. Recombinant adenoviral vector and methods of use
US5837520A (en) 1995-03-07 1998-11-17 Canji, Inc. Method of purification of viral vectors
ATE278794T1 (en) 1995-06-15 2004-10-15 Crucell Holland Bv PACKAGING SYSTEMS FOR HUMAN, HUMAN ADENOVIRUSES, FOR USE IN GENE THERAPY
US5789244A (en) 1996-01-08 1998-08-04 Canji, Inc. Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems
US6392069B2 (en) 1996-01-08 2002-05-21 Canji, Inc. Compositions for enhancing delivery of nucleic acids to cells
CA2177085C (en) 1996-04-26 2007-08-14 National Research Council Of Canada Adenovirus e1-complementing cell lines
US6248514B1 (en) 1996-07-09 2001-06-19 Canji, Inc. Methods for measuring viral infectivity
US6544769B1 (en) 1996-12-13 2003-04-08 Schering Corporation Compostions comprising viruses and methods for concentrating virus preparations
US6261823B1 (en) 1996-12-13 2001-07-17 Schering Corporation Methods for purifying viruses
US6146891A (en) 1997-01-31 2000-11-14 Schering Corporation Methods for cultivating cells and propagating viruses
AU757976B2 (en) 1998-02-17 2003-03-13 Schering Corporation Compositions comprising viruses and methods for concentrating virus preparations
US6670188B1 (en) * 1998-04-24 2003-12-30 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US5994134A (en) 1998-05-04 1999-11-30 Canji, Inc. Viral production process
US6649158B1 (en) * 1998-10-15 2003-11-18 Canji, Inc. Methods and compositions to induce antitumor response
US7691370B2 (en) * 1998-10-15 2010-04-06 Canji, Inc. Selectivity replicating viral vector
US7001770B1 (en) 1998-10-15 2006-02-21 Canji, Inc. Calpain inhibitors and their applications
US6430595B1 (en) 1999-05-20 2002-08-06 Cisco Technology, Inc. Method and apparatus for establishing a database used for correlating information gathered via SNMP
US20020064860A1 (en) 2000-11-29 2002-05-30 Schering Corporation Method for purifying adenoviruses
AU2004245074A1 (en) 2003-06-04 2004-12-16 Canji, Inc Methods and compositions for interferon therapy
US7026164B2 (en) * 2003-07-03 2006-04-11 Cell Genesys, Inc. Adenovirus packaging cell lines
ES2363912T3 (en) 2003-12-10 2011-08-19 Canji, Inc. PROCEDURES AND COMPOSITIONS FOR THE TREATMENT OF INTERFERON-RESISTANT TUMORS.
CN101208425B (en) 2004-12-13 2011-01-26 坎吉有限公司 Cell lines for production of replication-defective adenovirus
DE202007018553U1 (en) 2006-02-10 2008-10-16 Freie Universität Berlin Device for preparing biological samples

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DORONIN K ET AL: "Tumor-specific, replication-competent adenovirus vectors overexpressing the adenovirus death protein", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 74, no. 13, July 2000 (2000-07-01), pages 6147 - 6155, XP002162706, ISSN: 0022-538X *
HOWE ET AL: "Matching complementing functions of transformed cells with stable expression of selected viral genes for production of E1-deleted adenovirus vectors", VIROLOGY, ACADEMIC PRESS,ORLANDO, US, vol. 345, no. 1, 5 February 2006 (2006-02-05), pages 220 - 230, XP005252864, ISSN: 0042-6822 *
HOWE J A ET AL: "Evaluation of E1-mutant adenoviruses as conditionally replicating agents for cancer therapy.", MOLECULAR THERAPY : THE JOURNAL OF THE AMERICAN SOCIETY OF GENE THERAPY. NOV 2000, vol. 2, no. 5, November 2000 (2000-11-01), pages 485 - 495, XP002381689, ISSN: 1525-0016 *
HOWE J A ET AL: "Retinoblastoma growth suppressor and a 300-kDa protein appear to regulate cellular DNA synthesis", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 87, August 1990 (1990-08-01), pages 5883 - 5887, XP002134798, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
US20060270041A1 (en) 2006-11-30
EP1831352A2 (en) 2007-09-12
WO2006065827A2 (en) 2006-06-22
JP2011015696A (en) 2011-01-27
CN101208425B (en) 2011-01-26
JP2008522630A (en) 2008-07-03
MX2007007145A (en) 2007-08-20
US7851218B2 (en) 2010-12-14
JP4621743B2 (en) 2011-01-26
ATE516343T1 (en) 2011-07-15
WO2006065827A9 (en) 2006-08-24
CA2590943A1 (en) 2006-06-22
CA2590943C (en) 2013-10-22
EP1831352B1 (en) 2011-07-13
CN101208425A (en) 2008-06-25

Similar Documents

Publication Publication Date Title
WO2006065827A3 (en) Cell lines for production of replication-defective adenovirus
WO2001023597A3 (en) Cell lines and constructs useful in production of e1-deleted adenoviruses in absence of replication competent adenovirus
WO2007070392A3 (en) Adenoviral expression vectors having an expression cassette in the e1 region and an inactivated e2b polymerase
Imler et al. Novel complementation cell lines derived from human lung carcinoma A549 cells support the growth of E1-deleted adenovirus vectors.
WO2004001032A3 (en) Stable adenoviral vectors and methods for propagation thereof
WO2005001103A3 (en) Methods of generating chimeric adenoviruses and uses for such chimeric adenoviruses
AU5152998A (en) Improved adenovirus vectors
NZ594355A (en) Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
CA2177085A1 (en) Adenovirus e1-complementing cell lines
WO2001058940A3 (en) Adenoviral capsid containing chimeric protein IX
WO2001036650A3 (en) An oncolytic adenovirus
WO1998039464A3 (en) Adenovirus vectors containing heterologous transcription regulatory elements and methods of using same
DE69425989D1 (en) New complementation cell lines for defective adenoviral vectors
WO2006127956A3 (en) Rapid production of adenovirus-free recombinant adenovirus vectors
WO1998039467A3 (en) Adenovirus vectors specific for cells expressing carcinoembryonic antigen and methods of use thereof
AU2001294624A1 (en) Recombinant adenovirus vectors that are replication-competent in tert-expressing cells
Marcellus et al. Expression of p53 in Saos-2 osteosarcoma cells induces apoptosis which can be inhibited by Bcl-2 or the adenovirus E1B-55 kDa protein.
WO2008095027A3 (en) Adenoviral vector comprising herpes simplex virus type 1 thymidine kinase and a transgene for increasing the expression of the transgene
WO2004099422A3 (en) Adenovirus particles with enhanced infectivity of dendritic cells and particles with decreased infectivity of hepatocytes
WO2002096939A3 (en) Adenovirus protein ix, its domains involved in capsid assembly, transcriptional activity and nuclear reorganization
WO2005060515A3 (en) An oncolytic adenovirus
PL376573A1 (en) Adenovirus expressing genes in reverse order and use thereof
WO2008067025A3 (en) Oncolytic adenoviruses and uses thereof
JP2007507216A5 (en)
WO2000026395A3 (en) Bovine cells expressing adenovirus essential functions for propagation of recombinant adenoviral vectors

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200580048072.2

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2007545722

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/007145

Country of ref document: MX

Ref document number: 2590943

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2005853909

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2005853909

Country of ref document: EP